BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
BioCryst Pharmaceuticals (Nasdaq: BCRX) plans to present at the Jefferies Global Healthcare Conference in London on November 18, 2026. The presentation is scheduled for 8:30 a.m. ET. BioCryst also plans to present at the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 1, 2026, at 8:45 a.m. ET. Live audio webcasts and replays will be accessible through the Investors & Media section of its website.
BioCryst Pharmaceuticals (BCRX) reported third-quarter 2026 revenue of $180.3 million, alongside higher operating profit and net income than a year earlier. Revenue rose 13% year over year, with ORLADEYO contributing $174.8 million. Operating profit reached $53.3 million, versus $29.6 million; net income was $37.9 million, versus $12.9 million. Growth benefited from CareMed’s initial ORLADEYO inventory build.
The company raised its 2026 total revenue outlook to $715 million–$730 million from $690 million–$715 million, maintained ORLADEYO guidance of $625 million–$645 million, and lowered expected non-GAAP operating expenses to $415 million–$425 million. In October, the FDA approved ORLADEYO oral pellets for HAE patients aged 12 and older. BioCryst expects initial BCX17725 patient data by year-end 2026 and navenibart pivotal results in Q3 2027. Nine-month net loss was $605.5 million, including acquired research and development expense.
BioCryst Pharmaceuticals (BCRX) will present four abstracts on its hereditary angioedema portfolio at the ACAAI annual meeting November 12–16 in Phoenix.
The presentations cover clinical data and real-world outcomes for ORLADEYO (berotralstat) and interim results from the ALPHA-SOLAR trial of investigational navenibart. ORLADEYO posters address hospital and emergency department use, healthcare use after switching from another preventive therapy, and 48-week experience adjusting pediatric doses as children grow. The navenibart poster addresses long-term safety, efficacy and quality of life. Poster presentations are scheduled for November 13–15.
BioCryst Pharmaceuticals (BCRX) will report its third quarter 2026 financial results on November 4, 2026, followed by a management call.
The conference call and webcast will begin at 8:30 a.m. ET to discuss the results and provide a corporate update. A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) received FDA approval for ORLADEYO oral pellets to prevent hereditary angioedema attacks in patients aged 12 and older. The 150 mg once-daily formulation adds a pellet option alongside capsules for adults and adolescents, including those who have difficulty swallowing capsules. Hereditary angioedema (HAE) is the condition targeted by the preventive treatment.
Approval was based on chemistry, manufacturing and controls information and data demonstrating pellet safety and tolerability compared with capsules. Pellets were previously approved for U.S. patients aged 2 to <12 years in December 2025. Across two clinical studies, 150 mg capsules produced a mean attack-rate reduction of 91% at 96 weeks and an 88% reduction in rescue medication use. These results were reported for capsules, not the newly approved pellets.
BioCryst Pharmaceuticals (Nasdaq: BCRX) formed a seven-member Scientific Advisory Board to provide independent scientific and strategic guidance for its research and development activities.
Anthony Manning chairs the board, which will work with Chief Research and Development Officer Sandeep Menon and Chief Scientific Officer David Jenkins. Its remit includes pipeline expansion, external innovation opportunities, translational science, clinical development and regulatory strategy. BioCryst said external innovation is increasingly central to its approach to building its drug pipeline. The board will also help strengthen connections with scientific, medical and patient communities worldwide.
BioCryst (Nasdaq:BCRX) will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. A live audio webcast and replay will be available via the Investors & Media section of the company’s website.
BioCryst (Nasdaq:BCRX) announced that Japan’s Ministry of Health, Labor and Welfare approved once-daily ORLADEYO (berotralstat) as prophylactic therapy for pediatric hereditary angioedema (HAE) patients aged 2 to <12 years. The approval covers a sprinkle-like granule formulation designed for children and follows positive interim data from the APeX-P trial, which showed early and sustained reductions in monthly attack rates and a safety profile consistent with older patients. OrphanPacific holds marketing authorization in Japan. This is the second ORLADEYO approval in Japan and follows prior capsule and pediatric approvals in the U.S. and more than 45 countries.
BioCryst (Nasdaq:BCRX) reported Q2 2026 total net revenue of $218.3 million (+34% y-o-y), including ORLADEYO revenue of $158.2 million (+1% y-o-y; +10% on a comparable basis excluding Europe). GAAP operating profit was $98.5 million and non-GAAP operating profit was $113.2 million. Net income was $78.4 million (basic EPS $0.31).
The company recognized $55.7 million of revenue from a European navenibart license with an Irish affiliate of Neopharmed Gentili, from which it received $70 million upfront and is eligible for up to $275 million in milestones plus 18%–30% tiered royalties. BioCryst maintained 2026 ORLADEYO revenue guidance of $625–$645 million and raised total revenue guidance to $690–$715 million, while lowering non-GAAP operating expense guidance to $420–$440 million.
Cash, cash equivalents, restricted cash and investments totaled $354.0 million at June 30, 2026, with positive cash flow in Q2 even excluding the navenibart upfront. The company began shipping ORLADEYO oral pellets to pediatric HAE patients in August, completed enrollment in the pivotal ALPHA-ORBIT navenibart study, advanced BCX17725 toward data by year-end 2026, and announced discontinuation of internal discovery programs and closure of its Birmingham facility by end-2026 to focus on external innovation. BioCryst also engaged CareMed as its sole specialty pharmacy partner for ORLADEYO starting Q3 2026.
BioCryst (Nasdaq:BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update, with live and replay access via the investors section of the company website.